Biotech Values

[DewDiligence]

Lundbeck reports positive phase-2 results in AD for Lu AE58054 as addend to Aricept:

http://in.reuters.com/article/2012/05/29/us-lundbeck-alzheimers-idINBRE84S0BE20120529

Danish drugmaker Lundbeck said patients who took its Alzheimer's drug candidate Lu AE58054 in a phase 2 clinical trial achieved statistically significant improvement in cognitive performance when the compound was added to donepezil.

Lundbeck said the clinical study in 278 patients suffering from Alzheimer's disease had achieved its main target and that Lu AE58054 was also well-tolerated in combination with donepezil.

Lundbeck’s shares in Copenhagen (LUN.CO) were up about 2% yesterday, when this news was reported.